Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Opinion
Video
Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment
Panelists discuss how emerging antibody-drug conjugates (ADCs) in metastatic breast cancer (mBC) treatment demonstrate innovation through optimized drug-to-antibody ratios, novel payloads, and targeted approaches to different breast cancer subtypes. Key trials explore combinations with established therapies and potential for improved tolerability profiles. Additional notable studies include comparative effectiveness research between approved ADCs and investigation of biomarker-driven patient selection strategies to maximize therapeutic benefit while minimizing adverse effects.
Video content above has been prompted by the following:
- How do emerging ADCs in clinical trials (eg, DB-1303/BNT323, patritumab deruxtecan, zanidatamab) demonstrate innovative approaches to treating mBC?
- Aside from emerging ADCs, please describe other clinical trials that may be of interest to pharmacists in this space (eg, head-to-head comparisons of approved ADCs).
Related Videos
Related Content
